Carboxymethyllysine in dermal tissues of diabetic and nondiabetic patients with chronic renal failure: Relevance to glycoxidation damage

Nephron

Volumn 88, Issue 1, 2001, Pages 30-35

  Meng, Jing ^a   Sakata, Noriyuki ^a   Imanaga, Yoshinobu ^a   Takebayashi, Shigeo ^a   Nagai, Ryoji ^b   Horiuchi, Seikoh ^b  

^a FUKUOKA UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Carboxymethyllysine; Chronic renal failure; Collagen; Glycation; Glycoxidation

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBOXYMETHYLLYSINE; COLLAGEN; COLLAGENASE; PEPSIN A; PROTEINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC VALUE; DRUG ACCUMULATION; DRUG CLEARANCE; FEMALE; GLUCOSE OXIDATION; HEMODIALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ISOLATION; SKIN BIOPSY;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; COLLAGEN; DERMIS; DIABETIC NEPHROPATHIES; ENDOPEPTIDASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE, CHRONIC; LYSINE; MALE; MICE; MICE, INBRED BALB C; MIDDLE AGED;

EID: 0035022283     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000045955     Document Type: Article

References (33)

1. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-1321.
2. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW, Lyons TJ: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993;91:2470-2478.
3. Beisswenger PJ, Moore LL, Brinek-Johnsen T, Curphey TJ: Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 1993;92:212-217.
4. Horiuchi S: Advanced glycation end products (AGE) - modified proteins and their potential relevance to atherosclerosis. Trends Cardiovasc Med 1996;6:163-168.
5. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, Horiuchi S, Taniguchi N, Maeda K, Kinoshita T: Beta-2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-1252.
6. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T: Amyloid beta-2-microglobulin is modified with N-epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis. Kidney Int 1996;50:1303-1309.
7. Smith MA, Taneda S, Richey PL, Miyata S, Yan SD, Stern D, Sayre LM, Monnier VM, Perry G: Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc Natl Acad Sci USA 1994;91: 5710-5714.
8. Yan SD, Chen X, Schmidt AM, Brett J, Godman G, Zou YS, Scott CW, Caputo C, Frappier T, Smith MA, Perry G, Yen SH, Stern D: Glycated tau-protein in Alzheimer disease: A mechanism for induction of oxidant stress. Proc Natl Acad Sci USA 1994;91:7787-7791.
9. Thorpe SR, Baynes JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996;9:69-77.
10. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-412.
11. Fu MX, Knecht KJ, Thorpe SR, Baynes JW: Role of oxygen in cross-linking and chemical modification of collagen by glucose. Diabetes 1992;41(suppl 2):42-48.
12. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW: Glycation, glycoxidation, and cross-linking of collagen by glucose: Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994;43:676-683.
13. Odetti P, Fogarty J, Sell DR, Monnier VM: Chromatographic quantitation of plasma and crythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992;41:153-159.
14. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM: Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996;93:2353-2358.
15. Hricik DE, Schulak JA, Sell DR, Fogarty JF, Monnier VM: Effect of kidney or kidney-pancreas transplantation on plasma pentosidine. Kidney Int 1993;43:398-403.
16. Ikeda K, Higashi T, Sano H, Jinnouchi Y, Yoshida M, Araki T, Ueda S, Horiuchi S: N′-(carboxy-methyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. Biochemistry 1996;35: 8075-8083.
17. 2-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue protein. Biochemistry 1995;34:10872-10878.
18. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW: Technical note: The serum concentration of the advanced glycation end product N-epsilon-(carboxymethyl)-lysine is increased in uremia. Kidney Int 1997; 52:1064-1067.
19. Horie K, Miyata T, Maeda K, Miyata S, Sugiyama S, Sakai H, Strihou CY, Monnier VM, Witztum JL, Kurokawa K: Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions: Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997;100:2995-3004.
20. McEneny J, Loughrey CM, McNamee PT, Trimble ER, Young IS: Susceptibility of VLDL to oxidation in patients on regular haemodialysis. Atherosclerosis 1997;129:215-220.
21. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in hemodialysis. Q J Med 1994; 87:679-683.
22. Sutherland WH, Walker RJ, Ball MJ, Stapley SA, Robertson MC: Oxidation of low density lipoproteins from patients with renal failure or renal transplants. Kidney Int 1995;48:227-236.
23. Stegemann H, Stalder K: Determination of hydroxyproline. Clin Chim Acta 1967;18:267-273.
24. Horiuchi S, Araki N, Morino Y: Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. J Biol Chem 1991;266:7329-7332.
25. Meng J, Sakata N, Takebayashi S, Asano T, Futata T, Araki N, Horiuchi S: Advanced glycation end-products of the Maillard reaction in aortic pepsin-insoluble and pepsin-soluble collagen from diabetic rats. Diabetes 1996;45: 1037-1043.
26. Ahmed MU, Thorpe SR, Baynes JW: Identification of N-epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986;261:4889-4894.
27. Smith PR, Thornalley PJ: Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions: Studies with the model fructosamine. N-epsilon-(1-deoxy-D-fructos-1-yl)hippuryl-lysine. Eur J Biochem 1992;210:729-739.
28. Glomb MA, Monnier VM: Mechanism of protein modification by glyoxal and glycolaldehyde reactive intermediates of the Maillard reaction. J Biol Chem 1995;270:10017-10026.
29. Wells-Knecht KJ, Zyzak VD, Litchfield JE, Thorpe SR, Baynes JW: Mechanism of autoxidative glycosylation identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 1995;34:3702-3709.
30. Wells-Knecht MC, Thorpe SR, Baynes JW: Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 1995;34:15134-15141.
31. Schnider SL, Kohn RR: Effect of age and diabetes mellitus on the solubility and nonenzymatic glycosylation of human skin collagen. J Clin Invest 1981;67:1630-1635.
32. Sakata N, Meng J, Jimi S, Takebayashi S: Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. Atherosclerosis 1995;116:63-75.
33. Meng J, Sakata N, Takebayashi S, Asano T, Futata T, Nagai R, Ikeda K, Horiuchi S, Myint T, Taniguchi N: Glycoxidation in aortic collagen from STZ-induced diabetic rats and its relevance to vascular damage. Atherosclerosis 1998;136:355-365.